NOSTER’s drug discovery platform begins with gut microbial metabolites.
Metabolites are not simply biomarkers.
They are biologically active molecules that participate in physiological systems, interact with host biology, and contribute to the regulation of biological balance.

Within NOSTER, drug discovery is built upon the systematic understanding of these molecular functions.
Rather than asking only whether a molecule changes,
we ask why it changes,
how it functions,
and what biological systems it helps regulate.

Only then do we consider its therapeutic potential.

Drug discovery does not begin with compound screening alone.
It begins with defining molecules that can be understood, compared, and interpreted within a shared scientific framework.

Within the Noster Metabolite Reference Program (NMRP), metabolites are organized as Reference Unit possessing defined biological context, comparison framework, interpretation scope, and scientific accountability.
These structured molecular foundations provide the starting point for drug discovery.

Drug discovery is therefore not separate from research.
It is the natural extension of research conducted upon shared scientific foundations.

By organizing biological knowledge before therapeutic development begins, we seek to improve both scientific reproducibility and translational potential.

Many conventional drug discovery programs begin by identifying compounds that interact with predefined therapeutic targets.
Our approach is fundamentally different.
We begin by understanding biological systems.

We investigate how gut microbial metabolites participate in those systems, identify molecules with meaningful biological functions, and translate those discoveries into therapeutic opportunities.
This systems-oriented strategy allows therapeutic hypotheses to emerge from biology itself rather than from isolated molecular activity.

Instead of asking,
“Which compound binds to this target?”
we first ask,
“Which biological system has become unbalanced?”
“Which metabolites participate in restoring that balance?”

Drug discovery begins with understanding biology.
Therapeutic innovation follows.

The gut microbiota continuously transforms dietary components into biologically active metabolites.
These metabolites influence numerous physiological processes associated with:

Rather than acting independently, these molecules participate in interconnected biological networks linking environmental inputs with host physiology.

Because they occupy this interface between microbes and the human body, gut microbial metabolites provide unique opportunities for therapeutic discovery.
They offer insight not only into disease mechanisms but also into the biological systems that maintain health.

In many research fields, metabolites are treated primarily as biomarkers.
Within NOSTER, they are viewed differently.

Metabolites are functional components of biological systems.
They participate in signaling,
cellular communication,
immune regulation,
metabolic adaptation,
and physiological homeostasis.

Their biological importance lies not only in their presence,
but also in their relationships with surrounding molecular networks.
Understanding these relationships enables us to identify therapeutic opportunities grounded in biological function rather than statistical association alone.

Scientific innovation does not emerge simply from discovering new molecules.
It emerges from understanding how those molecules function within living systems.

By integrating metabolite science,
reference systems,
mechanistic biology,
and therapeutic development,
Noster seeks to establish a new scientific foundation for drug discovery.
One in which biological understanding precedes therapeutic design,
and where discoveries remain scientifically interpretable,
comparable,
and capable of supporting future innovation.

Every therapeutic program begins with scientific understanding.
At NOSTER, our drug discovery platform is supported by years of research into gut microbial metabolites, their biosynthesis, biological mechanisms, and relationships with human physiology.

Rather than beginning with a predefined therapeutic hypothesis, we begin by asking fundamental biological questions.
How are functional metabolites generated?
How do they interact with biological systems?
How do they contribute to health and disease?

Only after these questions are addressed do therapeutic opportunities emerge.
Drug discovery therefore begins not with compounds, but with biology.

Scientific discovery follows a progression.
A molecule is identified.
Its origin is clarified.
Its biological function is investigated.
Its mechanism is understood.
Its therapeutic relevance becomes apparent.

Each stage builds upon the previous one.
This progression allows scientific discoveries to evolve naturally into therapeutic innovation.

At NOSTER, we regard this progression as the scientific backbone of metabolite-based drug discovery.

HYA represents the first gut microbial lipid metabolite systematically investigated through NOSTER’s scientific platform.
Its discovery established more than a single research finding.
It opened an entirely new scientific perspective on how metabolites generated by gut microbes participate in regulating host physiology.

Over time, research has clarified:

This accumulated evidence provides one of the scientific foundations supporting our drug discovery platform.

The significance of HYA extends beyond a single molecule.
Its discovery illustrates how biological pathways connect:

Drug discovery therefore becomes the study of biological systems rather than isolated compounds.
Understanding these pathways enables therapeutic development grounded in biology instead of empirical screening alone.

No single publication establishes a therapeutic platform.
Scientific innovation emerges through the accumulation of evidence across multiple studies.
Each discovery contributes another layer of understanding.
Together, these layers create a foundation capable of supporting future therapeutic development.

For NOSTER, scientific accumulation is itself a strategic asset.
Drug discovery progresses not by isolated breakthroughs, but by continuously strengthening the biological foundations upon which future innovation depends.

The discovery of a metabolite is only the beginning.
Its true scientific significance lies in understanding how it participates in biological systems, influences cellular behavior, and contributes to the regulation of health and disease.

At NOSTER, we investigate how gut microbial metabolites influence host physiology through coordinated interactions among metabolites, receptors, cells, tissues, and biological networks.
Rather than viewing biological processes as isolated molecular events, we study them as integrated systems.

Every biological response begins with molecular interaction.
A metabolite interacts with a receptor.
The receptor initiates intracellular signaling.
Cells alter their biological behavior.
Tissues respond.
Physiological systems adapt.
Ultimately, disease progression—or recovery—may change.

Understanding these hierarchical relationships is essential for developing therapeutics grounded in biological mechanisms.
Mechanisms explain not only what changes,
but why those changes occur.

HYA represents one of the most comprehensively investigated gut microbial lipid metabolites within NOSTER’s research platform.
Over years of investigation, our research has progressively clarified its:

Rather than representing a single scientific discovery, HYA serves as a reference case demonstrating how metabolite science connects molecular discovery, mechanistic biology, and therapeutic development.
Its scientific value lies not only in the molecule itself, but in the framework through which its biological functions have been systematically understood.

Biological regulation rarely depends upon a single molecule.
Instead, physiological responses emerge through coordinated interactions among numerous molecules operating simultaneously.

Gut microbial metabolites participate in complex biological systems involving:

Understanding these interconnected relationships allows biological states to be interpreted as dynamic systems rather than isolated molecular events.
This systems-oriented perspective underlies all mechanistic research conducted at NOSTER.

Mechanistic research does more than explain biology.
It provides the scientific rationale for therapeutic development.

Mechanistic evidence supports:

Within NOSTER, mechanism is never regarded as the endpoint of discovery.
It serves as the bridge connecting molecular discovery with therapeutic innovation.

Noster approaches postbiotics as biologically active molecules rather than living gut microbes.
Rather than developing living microbes themselves as therapeutics, we focus on identifying the metabolites they produce and understanding how those molecules influence host physiology.

This molecular perspective allows therapeutic development to concentrate on:

By focusing directly on functional metabolites, drug discovery becomes centered on molecular mechanisms rather than microbial administration.
This approach represents one of the defining characteristics of NOSTER’s metabolite-based drug discovery platform.

Scientific discovery becomes meaningful only when it can be translated into clinical value.
At NOSTER, we are advancing multiple therapeutic programs based on gut microbial metabolites, spanning fundamental biology, preclinical research, clinical research, and future clinical development.

Each program is supported by accumulated biological evidence, mechanistic understanding, referenceable scientific knowledge, and an expanding intellectual property portfolio.
Together, these elements demonstrate how metabolite science can become a new foundation for therapeutic innovation.

Drug discovery is not a linear process.
Each stage informs the next.
Scientific understanding deepens continuously as biological evidence accumulates.

Rather than treating research and development as separate activities, NOSTER integrates them into a single scientific continuum.
From molecular discovery to clinical translation, every stage builds upon shared scientific foundations.

NOSTER is currently investigating therapeutic applications across multiple disease areas.
Representative development programs include:

Development stages differ according to the maturity of each program and include:

Each program evolves according to scientific evidence rather than predetermined timelines.

We are advancing clinical research and preclinical studies across multiple disease areas.
These studies demonstrate the potential of HYA as a therapeutic agent.

Every therapeutic program is supported by multiple layers of scientific evidence.
These include:

Rather than relying upon isolated findings, our pipeline is built upon accumulated scientific understanding developed over many years of research.
Each additional layer of evidence strengthens the biological rationale for therapeutic development.

Drug discovery requires more than promising biological activity.
Successful therapeutic development depends upon integrating:

By combining these scientific perspectives, NOSTER seeks to develop therapeutic programs grounded in biological understanding rather than empirical screening alone.

Scientific discovery alone cannot establish a sustainable therapeutic platform.
Innovation must also be protected.

NOSTER’s metabolite-based drug discovery programs are supported by an expanding international intellectual property portfolio protecting:

Scientific evidence and intellectual property evolve together as complementary foundations for future therapeutic innovation.

Gut microbial metabolites participate in numerous biological systems.
Rather than focusing on individual diseases independently, Noster investigates the biological mechanisms shared across multiple therapeutic areas.

Many chronic diseases arise through interconnected disturbances involving:

Understanding these shared biological systems creates opportunities for therapeutic innovation extending beyond conventional disease classifications.

Our research currently focuses on therapeutic areas including:

Although these diseases differ clinically, many share underlying biological mechanisms involving metabolite regulation and host responses.
By studying these common molecular pathways, we seek therapeutic opportunities capable of influencing multiple disease processes through shared biological mechanisms.

Conventional drug discovery often begins with a disease.
NOSTER begins with biology.

Disease represents one manifestation of biological imbalance.
By understanding the molecular systems underlying that imbalance, therapeutic opportunities may emerge across multiple clinical indications.

This systems-oriented perspective allows discoveries made in one therapeutic area to inform research in others.
Scientific knowledge therefore becomes cumulative rather than disease-specific.

As metabolite science continues to evolve, so too does its therapeutic potential.
Future opportunities may emerge wherever gut microbial metabolites influence biological systems.

Our objective is not simply to expand into additional disease areas.
It is to deepen scientific understanding of biological regulation and translate that understanding into meaningful therapeutic innovation.

Every therapeutic program begins with biological understanding.
Every biological insight contributes to future therapeutic possibilities.

At NOSTER, therapeutic innovation is built not upon isolated discoveries, but upon scientific foundations that remain interpretable, reproducible, and expandable over time.
This philosophy enables drug discovery that grows stronger as scientific knowledge accumulates.

Drug discovery requires evidence that extends beyond molecular discovery.
Before a therapeutic candidate advances toward clinical development, it must demonstrate reproducible biological activity, mechanistic relevance, and translational potential.

At NOSTER, proof-of-concept (PoC) research integrates molecular biology, experimental pharmacology, disease models, and metabolite science to evaluate the biological functions of gut microbial metabolites.

Our objective is not simply to determine whether a molecule works.
It is to understand why it works, how it works, and under what biological conditions it may become therapeutically meaningful.

Our preclinical research investigates multiple layers of scientific evidence, including:

Rather than evaluating isolated endpoints, we seek to establish coherent biological evidence that connects molecular mechanisms with disease biology.
This integrated approach strengthens the scientific rationale supporting future therapeutic development.

Proof-of-concept research is not the conclusion of discovery.
It represents the point at which biological understanding begins to demonstrate clinical relevance.

By integrating molecular evidence, biological mechanisms, pharmacology, and disease biology, NOSTER seeks to establish therapeutic candidates capable of advancing toward future clinical development.

Scientific rigor at this stage is essential.
Strong mechanistic evidence increases the likelihood that discoveries can successfully progress into translational research.

Every preclinical study contributes to a broader scientific foundation.
Experimental results are not viewed as isolated datasets.

They become part of an expanding body of biological knowledge supporting future:

In this way, every study contributes not only to a single project but also to the long-term evolution of metabolite science.

Transformative drug discovery cannot be achieved by a single organization.
Scientific innovation advances through collaboration built upon shared scientific foundations, complementary expertise, and long-term trust.

NOSTER works with universities, medical institutions, biotechnology companies, pharmaceutical companies, and strategic partners to accelerate the development of metabolite-based therapeutics.

Our objective is not merely to establish collaborations.
It is to build enduring scientific partnerships capable of creating lasting therapeutic value.

Every successful partnership begins with shared scientific values.
We seek collaborators who value:

Rather than pursuing collaboration based solely on organizational scale, we prioritize alignment in scientific philosophy and shared commitment to advancing metabolite science.

Metabolite-based drug discovery represents one of the fastest emerging fields in life science.
Its future depends upon international collaboration across scientific disciplines.

Noster actively expands global partnerships through:

These collaborations allow scientific discoveries to evolve beyond individual laboratories and contribute to future healthcare worldwide.

We welcome discussions with organizations possessing expertise in areas including:

Above all, we seek partners who share a commitment to advancing biologically meaningful therapeutics through scientific excellence.

Scientific breakthroughs rarely emerge from isolated efforts.
They arise when complementary knowledge, technologies, and perspectives converge.

Building the Future of Drug Discovery By combining metabolite science with global collaboration, NOSTER seeks to establish a new model of therapeutic innovation—one that integrates discovery, scientific validation, and practical implementation.

Every therapeutic discovery begins with scientific understanding.
At NOSTER, drug discovery begins with biologically meaningful metabolites, supported by rigorous scientific foundations, reference systems, and mechanistic research.

Our goal is not simply to discover new therapeutic molecules.
It is to establish an entirely new approach to drug discovery grounded in metabolite science.

By integrating biological understanding with long-term scientific infrastructure, we seek to create therapeutic innovation capable of benefiting future generations.

The future of medicine will not be shaped by molecules alone.
It will be shaped by our understanding of the biological systems in which those molecules function.

That future begins with science.
And science begins with understanding.

Let’s Explore the Future of Metabolite-Based Drug Discovery Together.

We welcome discussions with organizations seeking to advance therapeutic innovation through gut microbial metabolites.

Whether your interests involve collaborative research, licensing, co-development, translational science, or strategic partnerships, we look forward to exploring future opportunities together.